Avellino Labs, a leader precision medicine, was founded in 2008. Avellino operates globally and has received multiple awards. Avellino’s commitment to ophthalmology began with the first commercially available genetic test for corneal dystrophy. Avellino continues to innovate and will launch a next-generation sequencing (NGS) test for keratoconus in 2019. By performing a simple genetic test, physicians can now see beyond their scanning tests to identify genetic variants in their patients that are associated with keratoconus. Early detection means physicians can help patients well before progression of disease.
Avellino partnered with Ulster University in 2016 to develop siRNA and CRISPR gene editing programs, providing exciting world-first treatment options and treatment technologies that can also be applied to diseases beyond ophthalmology. These therapies have been proven in lab studies, and Avellino will proceed with human trials in the very near future.
→ Click here to visit the Avellino Labs website.